This ophthalmic solution is a fixed-dose combination medication formulated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The sterile liquid integrates two active pharmaceutical agents with distinct mechanisms of action to enhance aqueous humor outflow and decrease fluid production. Latanoprost, a prostaglandin analogue, increases uveoscleral outflow, while netarsudil, a Rho kinase inhibitor, targets the trabecular meshwork to improve conventional drainage. This dual-action approach aims to achieve significant physiological reduction in ocular pressure to prevent progressive optic nerve damage. The 2.5mL multi-dose vial is designed for precise topical administration to the ocular surface.

Key Features

• Dual Mechanism Action: Combines a prostaglandin F2-alpha analogue with a Rho kinase inhibitor to address multiple pathways of aqueous humor dynamics.
• Trabecular Meshwork Target: Specifically utilizes netarsudil to reduce resistance within the primary drainage pathway of the eye.
• Uveoscleral Outflow Enhancement: Includes latanoprost to facilitate secondary fluid drainage, providing a synergistic effect on intraocular pressure.
• Consistent 24-Hour Control: Formulated for once-daily nocturnal administration to maintain stable ocular tension levels throughout the diurnal cycle.
• Sterile Ophthalmic Solution: Manufactured under strict aseptic conditions to ensure safety and efficacy for direct topical application to the conjunctival sac
• Storage and Handling Specifications